CHICAGO, June 21, 2007 /PRNewswire/ --
What and When
Data from the PROactive and CHICAGO studies of ACTOS(R) (pioglitazone HCl) will be presented in poster format at the 67th Scientific Sessions of the American Diabetes Association in Chicago:
-- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3 years: results from PROactive; Poster 0553-P presented on Saturday, June 23, from 12:30- 2:30 p.m. and 6:00-7:15 p.m. -- The relationship between renal dysfunction and major cardiovascular outcomes in patients with diabetes: experience from PROactive; Poster 0670-P presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00- 7:15 p.m. -- Effects of pioglitazone in patients with type 2 diabetes and reduced glomerular filtration rate: an analysis from PROactive; Poster 0671-P presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00-7:15 p.m. -- Effects of long-term treatment with pioglitazone on lipid levels in patients receiving statin therapy at baseline in the PROactive study; Poster 0905-P presented on Sunday, June 24, from 12-2 p.m. and 6:15- 7:30 p.m. -- Comparative effects of pioglitazone and glimepiride on lipoprotein subfractions: results from the CHICAGO Trial; Poster 0906-P presented on Sunday, June 24, from 12-2 p.m. and 6:15-7:30 p.m. -- Long-term cost-effectiveness analysis on ACTOS for the USA from PROactive; Poster 1209-P presented on Sunday, June 24, from 12-2 p.m. and 6:15-7:30 p.m.
ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for use for t ype 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas or metformin.
ACTOS is not for everyone. ACTOS can cause fluid retention that may lead to or worsen heart failure, so tell your doctor if you have a history of these conditions. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath while taking ACTOS. If you have moderate to severe heart failure, ACTOS is not recommended. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter.
Do not take ACTOS if you have active liver disease. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flu-like symptoms, mild to moderate swelling of legs and ankles, and anemia. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.
Please visit the ACTOS Web site at www.actos.com for Complete Prescribing Information.
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc., is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral products for diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit www.tpna.com.
ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.
North America, Inc.
CONTACT: Jocelyn M. Gerst of Takeda Global Research & Development,+1-224-554-5542, ; or Amy Losak of Ketchum, +1-646-935-3917,cell, +1-917-865-6688, , for Takeda PharmaceuticalsNorth America, Inc. email@example.com firstname.lastname@example.org
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company